Next report date
Report period
Q1 2024
EPS estimate
−1.09USD
Revenue estimate
—
−6.15USD
−35.20 MUSD
7.32 M
About Elicio Therapeutics, Inc.
Sector
Industry
CEO
Robert T. Connelly
Website
Headquarters
Boston
Employees (FY)
32
Founded
2011
FIGI
BBG00444GM02
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cancer immunotherapies. It focuses on its Amphiphile platform for trafficking lymph nodes. The company was founded by Darrell Irvine in August 2011 and is headquartered in Boston, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ELTX is 8.85 USD — it has decreased by 3.80% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Elicio Therapeutics, Inc. stocks are traded under the ticker ELTX.
Elicio Therapeutics, Inc. is going to release the next earnings report on May 14, 2024. Keep track of upcoming events with our Earnings Calendar.
ELTX stock is 4.55% volatile and has beta coefficient of −1.19. Check out the list of the most volatile stocks — is Elicio Therapeutics, Inc. there?
ELTX earnings for the last quarter are −1.27 USD per share, whereas the estimation was −0.80 USD resulting in a −58.75% surprise. The estimated earnings for the next quarter are −1.03 USD per share. See more details about Elicio Therapeutics, Inc. earnings.
Elicio Therapeutics, Inc. revenue for the last quarter amounts to 653.00 K USD despite the estimated figure of 1.35 M USD. In the next quarter revenue is expected to reach 625.00 K USD.
Yes, you can track Elicio Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
ELTX stock has fallen by 4.74% compared to the previous week, the month change is a 29.58% rise, over the last year Elicio Therapeutics, Inc. has showed a 28.26% increase.
ELTX net income for the last quarter is −8.95 M USD, while the quarter before that showed −10.66 M USD of net income which accounts for 16.03% change. Track more Elicio Therapeutics, Inc. financial stats to get the full picture.
Today Elicio Therapeutics, Inc. has the market capitalization of 94.13 M, it has increased by 1.14% over the last week.
No, ELTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ELTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Elicio Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of May 1, 2024, the company has 32.00 employees. See our rating of the largest employees — is Elicio Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Elicio Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Elicio Therapeutics, Inc. stock shows the buy signal. See more of Elicio Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Elicio Therapeutics, Inc. future price: according to them, ELTX price has a max estimate of 10.00 USD and a min estimate of 10.00 USD. Read a more detailed Elicio Therapeutics, Inc. forecast: see what analysts think of Elicio Therapeutics, Inc. and suggest that you do with its stocks.